Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nacamed AS has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner is TIEN, LUCY MINYU, who is responsible for 1 busiest_examiner_pending action. This indicates that the current pending portfolio is under the review of the identified individual in the specified department. The alignment of the 1 pending action with the 1 distinct art unit suggests a specific technical focus for the current filings in the biotechnology sector.
For the practitioner, having the workload concentrated in this manner means that prosecution efforts are focused on a specific set of requirements. TIEN, LUCY MINYU handles the pending work, so the strategy does not need to account for multiple examiner styles or different art unit practices. The focus remains on the technical requirements identified in the Biotechnology & Pharmaceuticals sector. This concentration allows for a singular approach to addressing the patent office without the need to reconcile conflicting feedback from different examiners. Resolving the 1 pending office action will depend on meeting the specific criteria of the 1 distinct examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIEN, LUCY MINYU | 1 | 59.3% | +39.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556513 | SILICON PARTICLES FOR DRUG DELIVERY | TIEN, LUCY MINYU | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556513 | SILICON PARTICLES FOR DRUG DELIVERY | TIEN, LUCY MINYU | 1612 | §103§112DP | Final Rejection | — | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial